Overview of the drug development pipeline for axillary hyperhidrosis
It has been observed that axillary hyperhidrosis is a medical condition in which the body produces excessive sweat in the underarms. The individuals with axillary hyperhidrosis sweat up to five times the amount that is necessary to regulate the body temperature. The causes of axillary hyperhidrosis can be genetic, so if a family member suffers from the condition, the person is more likely to inherit it. High consumption of caffeine is also one of the causes of axillary hyperhidrosis. This condition usually tends to begin during the onset of puberty, but symptoms can appear up to the age of 25 years. Antiperspirants are considered the most efficient approach for the treatment of axillary hyperhidrosis.
According to this pipeline analysis report, all of the drug molecules in the pipeline are being developed for axillary hyperhidrosis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Want a bigger picture? Try a FREE sample of this report now!
Pipeline analysis report on drug development for axillary hyperhidrosis: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of axillary hyperhidrosis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in our pipeline analysis report are:
- Allergan
- Brickwell Biotech
- Dr. August Wolff
- GlaxoSmithKline
- TheraVida
Therapeutic assessment of the drug development pipeline for axillary hyperhidrosis by route of administration
- Topical
The topical route of administration (ROA) involves the application of the drug molecules directly on the skin, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for axillary hyperhidrosis by target
- Muscarinic acetylcholine receptors (mAChRs)
- Acetylcholine (ACh)
According to the pipeline analysis report, most of the molecules that are currently in the drug pipeline for axillary hyperhidrosis are being targeted on muscarinic acetylcholine receptors and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug molecules in the various development stages for axillary hyperhidrosis?
- What are the companies that are currently involved in the development of drug molecules for axillary hyperhidrosis?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.